Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CATX

Perspective Therapeutics Inc

Apr 26 • 04:00PM ET

1.58

Dollar change -0.02
Percentage change -1.25	%

Healthcare • Medical Devices • USA • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.09	Insider Own	20.55%	Shs Outstand	586.92M	Perf Week	5.33%
Market Cap	927.33M	Forward P/E	-	EPS next Y	-0.10	Insider Trans	105.64%	Shs Float	466.28M	Perf Month	31.67%
Income	-23.91M	PEG	-	EPS next Q	-0.02	Inst Own	13.09%	Short Float	2.24%	Perf Quarter	152.64%
Sales	8.84M	P/S	104.90	EPS this Y	48.53%	Inst Trans	-1.05%	Short Ratio	2.45	Perf Half Y	476.64%
Book/sh	0.35	P/B	4.49	EPS next Y	-18.09%	ROA	-27.07%	Short Interest	10.43M	Perf Year	174.97%
Cash/sh	0.03	P/C	51.58	EPS next 5Y	-	ROE	-29.53%	52W Range	0.20 - 1.77	Perf YTD	293.03%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-7.69%	ROI	-23.50%	52W High	-10.73%	Beta	1.46
Dividend TTM	-	Quick Ratio	2.55	Sales past 5Y	-	Gross Margin	27.13%	52W Low	670.73%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	2.67	EPS Y/Y TTM	-45.00%	Oper. Margin	-346.50%	RSI (14)	60.72	Volatility	6.79% 9.37%
Employees	119	Debt/Eq	0.03	Sales Y/Y TTM	-19.63%	Profit Margin	-270.46%	Recom	1.00	Target Price	1.68
Option/Short	No / Yes	LT Debt/Eq	0.03	EPS Q/Q	-29.02%	Payout	-	Rel Volume	1.10	Prev Close	1.60
Sales Surprise	-83.33%	EPS Surprise	20.00%	Sales Q/Q	27.26%	Earnings	Mar 28 BMO	Avg Volume	4.26M	Price	1.58
SMA20	6.65%	SMA50	29.46%	SMA200	155.50%	Trades		Volume	4,684,382	Change	-1.25%

Apr-08-24 08:00AM	Perspective Therapeutics to Participate at Upcoming April Investor Conferences (GlobeNewswire)
Mar-30-24 05:31AM	Perspective Therapeutics Inc (CATX) Reports Fiscal Year 2023 Financial Results (GuruFocus.com)
Mar-28-24 07:30AM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results (GlobeNewswire)
Mar-19-24 10:39AM	Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal (The Wall Street Journal) +16.06%
Mar-18-24 08:00AM	Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma (GlobeNewswire) -9.81%
08:00AM	Loading…
Mar-11-24 08:00AM	Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 (GlobeNewswire)
Mar-05-24 08:00AM	Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility (GlobeNewswire)
Mar-04-24 09:45AM	Perspective Therapeutics Announces $87.4 Million Private Placement (GlobeNewswire) +11.72%
Feb-26-24 08:00AM	Perspective Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) -6.25%
Feb-20-24 06:30AM	These Drug Companies Are Going Nuclear to Fight Cancer (The Wall Street Journal)
Feb-12-24 08:00AM	Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -7.79%
Feb-08-24 10:00AM	Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline (Zacks) -5.72%
Feb-01-24 08:00AM	Perspective Therapeutics Introduces Pre-Targeting Theranostic Technology Platform (GlobeNewswire)
Jan-22-24 04:05PM	Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement (GlobeNewswire)
Jan-18-24 07:00AM	Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement (GlobeNewswire) +26.12%
04:05PM	Loading…
Jan-17-24 04:05PM	Perspective Therapeutics Announces Proposed Public Offering (GlobeNewswire)
08:00AM	Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT--NET and [(212)Pb]VMT01 (GlobeNewswire)
Jan-09-24 08:00AM	Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability (GlobeNewswire) +9.15%
08:00AM	Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics (GlobeNewswire)
Jan-05-24 08:00AM	Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment (GlobeNewswire) +8.77%
Jan-02-24 08:00AM	Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-23 08:00AM	Perspective Therapeutics Divests Brachytherapy Business (GlobeNewswire) -5.24%
Dec-07-23 08:00AM	Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT--NET to Treat Refractory or Relapsed Neuroendocrine Tumors (GlobeNewswire)
Nov-28-23 08:00AM	Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT--NET by Clinical Collaborators in Germany (GlobeNewswire)
Nov-27-23 08:00AM	Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals (GlobeNewswire)
Nov-16-23 08:00AM	Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy (GlobeNewswire)
Nov-14-23 04:25PM	Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights (GlobeNewswire)
Nov-08-23 08:00AM	Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT--NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors (GlobeNewswire)
Oct-16-23 08:00AM	Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma (GlobeNewswire)
Oct-10-23 08:00AM	Perspective Therapeutics VMT--NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium (GlobeNewswire)
04:05PM	Loading…
Oct-05-23 04:05PM	Perspective Therapeutics Cesium-131 Featured at the American Society for Radiation Oncologys Annual Conference (GlobeNewswire)
Sep-12-23 08:00AM	Perspective Announces Presentation of Positive Early Clinical Data for VMT--NET at the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Sep-11-23 08:00AM	Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Aug-30-23 08:17AM	Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023 (GlobeNewswire)
Aug-28-23 08:00AM	Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Aug-11-23 09:15AM	Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:11AM	Perspective Therapeutics: Q2 Earnings Snapshot (AP Finance)
08:05AM	Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma (GlobeNewswire)
08:00AM	Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights (GlobeNewswire)
Aug-09-23 08:05AM	Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment (GlobeNewswire)
Jun-27-23 08:00AM	Perspective Therapeutics Cesium-131 Featured at the American Brachytherapy Societys Annual Conference (GlobeNewswire)
Jun-21-23 08:00AM	Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates (GlobeNewswire)
Jun-16-23 08:00AM	Perspective Therapeutics Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Societys Annual Meeting (GlobeNewswire) +24.37%
Jun-08-23 08:00AM	Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference (GlobeNewswire)
May-28-23 06:36PM	The Best Penny Stock to Buy Now ZH vs CATX vs LMFA (InvestorPlace)
May-24-23 08:10AM	Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS) (GlobeNewswire)
May-16-23 05:02AM	Perspective Therapeutics: Fiscal Q3 Earnings Snapshot (AP Finance) -21.54%
May-15-23 08:22PM	Perspective Therapeutics Reports First Quarter Fiscal 2023 Results (GlobeNewswire)
05:35PM	Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:49PM	Perspective Therapeutics Announces Changes to the Board of Directors (GlobeNewswire)

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1998 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Austin Mark John	VP Finance/Prin Fin&Acct Offic	Apr 23 '24	Option Exercise	0.36	30,000	10,800	84,030	Apr 24 04:35 PM
Lantheus Alpha Therapy, LLC	10% Owner	Mar 06 '24	Buy	0.95	60,431,039	57,409,487	116,773,394	Mar 08 11:24 AM
Williamson Robert F III	Director	Jan 30 '24	Buy	0.71	127,206	90,710	338,761	Feb 01 04:53 PM
Williamson Robert F III	Director	Jan 29 '24	Buy	0.64	25,266	16,170	211,555	Jan 30 04:57 PM
Williamson Robert F III	Director	Jan 26 '24	Buy	0.56	110,613	62,304	186,289	Jan 30 04:57 PM
Williamson Robert F III	Director	Jan 25 '24	Buy	0.49	22,134	10,846	75,676	Jan 26 05:38 PM
Puhlmann Markus	Chief Medical Officer	Jan 24 '24	Buy	0.50	280,000	139,888	1,375,425	Jan 26 05:40 PM
Williamson Robert F III	Director	Jan 24 '24	Buy	0.49	29,862	14,632	53,542	Jan 26 05:38 PM
Williamson Robert F III	Director	Dec 21 '23	Buy	0.33	3,663	1,203	3,663	Dec 26 05:00 PM
Puhlmann Markus	Chief Medical Officer	Dec 19 '23	Buy	0.34	400,000	137,000	1,095,425	Dec 19 07:09 PM
Williamson Robert F III	Director	Dec 19 '23	Buy	0.32	13,680	4,378	23,680	Dec 19 07:10 PM
Hunt Jonathan Robert	Chief Financial Officer	Dec 18 '23	Buy	0.26	125,000	32,338	316,710	Dec 19 07:11 PM
Puhlmann Markus	Chief Medical Officer	Dec 18 '23	Buy	0.26	60,419	15,461	695,425	Dec 19 07:09 PM
Williamson Robert F III	Director	Dec 18 '23	Buy	0.26	10,000	2,600	10,000	Dec 19 07:10 PM
Woods Lori A	Director	Dec 15 '23	Buy	0.27	152,962	41,284	1,519,738	Dec 18 04:16 PM
Puhlmann Markus	Chief Medical Officer	Dec 15 '23	Buy	0.27	135,006	36,276	635,006	Dec 19 07:09 PM
Woods Lori A	Director	Dec 14 '23	Buy	0.27	32,238	8,704	1,366,776	Dec 18 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CATX

Perspective Therapeutics Inc

Upgrade your FINVIZ experience